ArticlePloS one2026
Effect of HIV-1 subtype-specific Tat protein polymorphisms on Tat-TAR interaction.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHIV Tat protein is responsible for HIV replication activation and interacts with the TAR RNA element for its function. Genetic polymorphisms in the Tat protein sequence can affect its interaction with the TAR element. Previous studies focusing on HIV subtypes B and C found that substitutions such as C31S, R57S, and Q63E can alter the binding conformations of the Tat protein and TAR element. However, it is not known if polymorphisms in other HIV subtypes can also affect Tat-TAR interactions. This study, therefore, aims to identify subtype-specific polymorphisms in the Tat protein and their effects on Tat-TAR interactions.
methodsHIV Tat protein sequences from subtypes A, A1, A3, A6, B, C, D, CRF01_AE, and CRF02_A were retrieved from the HIV Los Alamos Database. The sequences were aligned and used to generate consensus sequences, which were subsequently used to identify subtype-specific Tat protein polymorphisms. The sequences were used to generate 3D models of the Tat protein using AlphaFold2, which were then used in molecular docking and molecular dynamics simulations over 200 ns using HDOCK and AMBER20, respectively, to identify the effects of subtype-specific polymorphisms on binding affinity and interaction with the TAR element.
resultsOur results show that subtypes A6, C, and CRF02_AG have higher affinity for TAR (with binding energies of -126.8, -123.2, and -123.3 kcal/mol, respectively). On the contrary, subtypes A3 and A1 had the weakest binding affinity to TAR, with binding energies of -63.3 and -57.5 kcal/mol, respectively. The increased and decreased affinity of Tat protein towards the TAR element may be attributed to subtype-specific polymorphisms (A3: K29A and R53K, A1: R57G, A6: K53R, Q54H, and V69I, C: V69I, C31S, and 58A, CRF02_AG: N24K and N29K).
conclusionThe results of the study suggest that subtype-specific polymorphisms can affect Tat-TAR interactions, allowing certain subtypes to interact much more strongly with TAR. This finding may have implications for the subtype-specific disease pathogenesis mediated by the Tat protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.